The Claims Defining the Invention are as Follows:

1. A crystal of (R)-N-(1-(3-(cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide having at least five or more diffraction angle ($2\theta \pm 0.2°$) peaks selected from the group consisting of 7.3°, 11.8°, 14.5°, 14.8°, 16.8°, 17.5°, 18.6°, 19.5°, 20.4°, 23.9°, 24.4°, 25.7°, 26.8°, and 31.5° in a powder X-ray diffraction spectrum.

2. The crystal according to claim 1, having an endothermic peak at 108°C ± 5°C in differential scanning calorimetry.

3. The crystal according to claim 1 or claim 2, having crystal data shown below obtained by single crystal analysis of the crystal:

Crystal system: Orthorhombic system

Space group: $P2_12_12_1$ (No. 19)

Lattice constant: a = 9.3998(5) Å

b = 10.3585(5) Å

c = 23.5111(10) Å

Unit cell volume: 2289.22(19) $Å^3$, and

Z value: 4.

4. A pharmaceutical composition comprising the crystal according to any one of claims 1 to 3.

5. A pharmaceutical composition for oral administration, comprising the crystal according to any one of claims 1 to 3.

6. The crystal according to any one of claims 1 to 3 for use as a medicine.